Hogan Lovells advises Perspective Therapeutics on US$87.4 million private placement financing

In the private placement, Perspective sold an aggregate of 92,009,981 shares of its common stock to a select group of institutional accredited investors at a price of US$0.95 per share, representing the closing price per share of Perspective’s common stock on the NYSE American as of March 1, 2024. The private placement closed on March 6, 2024.

Oppenheimer & Co. acted as lead placement agent for the private placement. B. Riley Securities acted as a placement agent, and JonesTrading Institutional Services LLC and LifeSci Capital acted as co-placement agents for the private placement.

Perspective is a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. Perspective has a proprietary technology that utilizes the alpha emitting isotope Lead-212 to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. Perspective is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.

Perspective intends to use the proceeds from the private placement for general corporate and working capital purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, capital expenditures, acquisitions of new technologies, products or businesses and investments.

The Hogan Lovells team was led by partners Andrew Strong (Houston) and Stephen Nicolai (Philadelphia), senior associate Amanda Brown (Philadelphia), and associates Tyler Glass and Kayvon Paul (both Philadelphia).